T cell-dependence of lassa fever pathogenesis

PLoS Pathogens

Volumn 6, Issue 3, 2010, Pages

  Flatz, Lukas ^a,b   Rieger, Toni ^c   Merkler, Doron ^d   Bergthaler, Andreas ^a,b,g   Regen, Tommy ^d   Schedensack, Mariann ^d   Bestmann, Lukas ^e,f   Verschoor, Admar ^b,h   Kreutzfeldt, Mario ^d   Brück, Wolfgang ^d   Hanisch, Uwe Karsten ^d   Günther, Stephan ^c   Pinschewer, Daniel D ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Unilabs   (France)

^g INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE SYNTHASE; BETA 2 MICROGLOBULIN; INTERLEUKIN 12P40; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; IMMUNE RESPONSE; INFECTION PREVENTION; INNATE IMMUNITY; LASSA FEVER; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; RISK FACTOR; T CELL DEPLETION; T LYMPHOCYTE; VIREMIA; ANIMAL; ARENAVIRUS; C57BL MOUSE; GENETICS; IMMUNOLOGY; LASSA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; MOUSE MUTANT; VIROLOGY;

LASSA VIRUS; MURINAE; MUS;

ANIMALS; ARENAVIRUS; BETA 2-MICROGLOBULIN; INTERLEUKIN-12 SUBUNIT P40; LASSA FEVER; LASSA VIRUS; MACROPHAGES; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MONOCYTES; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 77950397232     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000836     Document Type: Article

References (68)

1. Buckley SM, Casals J, Downs WG (1970) Isolation and antigenic characterization of Lassa virus. Nature 227: 174.
2. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES (1987) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437-444.
3. Haas WH, Breuer T, Pfaff G, Schmitz H, Kohler P, et al. (2003) Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 36: 1254-1258. (Pubitemid 36629934)
4. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama 287: 2391-2405. (Pubitemid 34493202)
5. Charrel RN, de Lamballerie X (2003) Arenaviruses other than Lassa virus. Antiviral Res 57: 89-100.
6. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110-121.
7. Gunther S, Lenz O (2004) Lassa virus. Crit Rev Clin Lab Sci 41: 339-390.
8. Halstead SB, O'Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265: 739-741.
9. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527-533.
10. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. (2003) Original antigenic sin and apopotosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921-927. (Pubitemid 36889936)
11. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, et al. (2001) Strong HLA class I - restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 184: 1369-1373.
12. Lan NT, KikuchiM, Huong VT, Ha do Q, Thuy TT, et al. (2008) Protective and Enhancing HLA Alleles, HLA-DRB1*0901 and HLA-A*24, for Severe Forms of Dengue Virus Infection, Dengue Hemorrhagic Fever and Dengue Shock Syndrome. PLoS Negl Trop Dis 2: e304. doi:10.1371/journal.pntd.0000304.
13. Chen YC, Wang SY (2002) Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 76: 9877-9887.
14. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, et al. (2008) CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453: 672-676.
15. Hatch S, Mathew A, Rothman A (2008) Dengue vaccine: opportunities and challenges. IDrugs 11: 42-45.
16. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
17. Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202: 1075-1080.
18. Openshaw PJ, Tregoning JS (2005) Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18: 541-555. (Pubitemid 40995115)
19. Mahanty S, Bausch DG, Thomas RL, Goba A, Bah A, et al. (2001) Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 183: 1713-1721. (Pubitemid 32523233)
20. ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, et al. (2004) Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 190: 1821-1827.
21. Lukashevich IS, Tikhonov I, Rodas JD, Zapata JC, Yang Y, et al. (2003) Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J Virol 77: 1727-1737. (Pubitemid 36109984)
22. Schmitz H, Kohler B, Laue T, Drosten C, Veldkamp PJ, et al. (2002) Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 4: 43-50. (Pubitemid 34127990)
23. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163: 2347-2370. (Pubitemid 37466478)
24. Linderholm M, Groeneveld PH, Tarnvik A (1996) Increased production of nitric oxide in patients with hemorrhagic fever with renal syndrome-relation to arterial hypotension and tumor necrosis factor. Infection 24: 337-340. (Pubitemid 26356496)
25. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78: 10370-10377. (Pubitemid 39258362)
26. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, et al. (1996) Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J Virol 70: 2208-2214. (Pubitemid 26087581)
27. McCormick JB, King IJ, Webb PA, Johnson KM, O'Sullivan R, et al. (1987) A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155: 445-455.
28. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT, Jr., et al. (1987) Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 134: 5-68.
29. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, et al. (1982) Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107: 349-356.
30. Winn WC, Jr., Monath TP, Murphy FA, Whitfield SG (1975) Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic. Arch Pathol 99: 599-604.
31. Edington GM, White HA (1972) The pathology of Lassa fever. Trans R Soc Trop Med Hyg 66: 381-389.
32. Frame JD, Baldwin JM, Jr., Gocke DJ, Troup JM (1970) Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19: 670-676.
33. McCormick JB, Walker DH, King IJ, Webb PA, Elliott LH, et al. (1986) Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 35: 401-407.
34. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB (2000) Effective vaccine for lassa fever. J Virol 74: 6777-6783.
35. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al. (2005) Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2: e183. doi:10.1371/journal.pmed.0020183.
36. Lukashevich IS (1985) Lassa virus lethality for inbred mice. Ann Soc Belg Med Trop 65: 207-209.
37. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, et al. (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051. (Pubitemid 27265987)
38. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, et al. (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155: 456-464.
39. Fink J, Gu F, Vasudevan SG (2006) Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 16: 263-275. (Pubitemid 44140722)
40. Kiley MP, Lange JV, Johnson KM (1979) Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2: 738.
41. Lukashevich IS, Patterson J, Carrion R, Moshkoff d, Ticer A, et al. (2005) A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79: 13934-13942.
42. Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, et al. (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80: 8351-8361. (Pubitemid 44384848)
43. Jahrling PB, Peters CJ (1986) Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med Microbiol Immunol (Berl) 175: 165-167.
44. Carrion R, Jr., Brasky K, Mansfield K, Johnson C, Gonzales M, et al. (2007) Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol 81: 6482-6490. (Pubitemid 46878053)
45. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
46. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA (1996) Impaired T cellmediated macrophage activation in CD40 ligand-deficient mice. J Immunol 156: 8-11. (Pubitemid 26006941)
47. Tian L, Noelle RJ, Lawrence DA (1995) Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 25: 306-309.
48. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, et al. (1995) Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 25: 1125-1128.
49. Lowenstein CJ, Padalko E (2004) iNOS (NOS2) at a glance. J Cell Sci 117: 2865-2867.
50. Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, et al. (2008) An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med 205: 1269-1276.
51. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, et al. (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96-105.
52. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, et al. (2004) Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 172: 2861-2869. (Pubitemid 38263671)
53. Lukashevich IS, Maryankova R, Vladyko AS, Nashkevich N, Koleda S, et al. (1999) Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol 59: 552-560. (Pubitemid 29523158)
54. Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, et al. (1986) T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J Exp Med 164: 1075-1092.
55. Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, et al. (2000) Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 157: 1671-1683.
56. Sato K, Kadiiska MB, Ghio AJ, Corbett J, Fann YC, et al. (2002) In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS. FASEB J 16: 1713-1720.
57. Clark IA (2007) The advent of the cytokine storm. Immunol Cell Biol 85: 271-273.
58. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927. (Pubitemid 36402840)
59. Oehen S, Hengartner H, Zinkernagel RM (1991) Vaccination for disease. Science 251: 195-198.
60. Jahrling PB, Smith S, Hesse RA, Rhoderick JB (1982) Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 37: 771-778.
61. Jahrling PB, Frame JD, Smith SB, Monson MH (1985) Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg 79: 374-379.
62. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485. (Pubitemid 47529331)
63. Koller BH, Marrack P, Kappler JW, Smithies O (1990) Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science 248: 1227-1230.
64. Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H (1993) Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 5: 957-964. (Pubitemid 23241767)
65. Lecompte E, Fichet-Calvet E, Daffis S, Koulemou K, Sylla O, et al. (2006) Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis 12: 1971-1974.
66. Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, et al. (2004) Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 78: 3162-3169. (Pubitemid 38314376)
67. Pinschewer DD, Perez M, Jeetendra E, Bächi T, Horvath E, et al. (2004) Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 114: 988-993. (Pubitemid 39578727)
68. Merkler D, Horvath E, Bruck W, Zinkernagel RM, de la Torre JC, et al. (2006) "Viral déjà vu" elicits organ-specific immune disease independent of reactivity to self. J Clin Invest 116: 1254-1263.